Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to examine the safety of Ipilimumab and patterns of use in the treatment of unresectable or metastatic melanoma in the post-approval setting


Clinical Trial Description

Time Perspective: this study does have a retrospective component involving a subset of patients ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01511913
Study type Observational
Source Bristol-Myers Squibb
Contact
Status Completed
Phase
Start date June 3, 2012
Completion date December 12, 2019

See also
  Status Clinical Trial Phase
Terminated NCT05050006 - ITIL-168 in Advanced Melanoma Phase 2